This week's Brexit downsides: half a billion in extra costs to import food, the collapse of trade talks with Canada and more.

British pharmacists are struggling to get their hands on certain medicines for cancer, epilepsy, diabetes and menopause as drug supply issues intensify in the country.

Global issues are factor but experts say there are problems peculiar to Britain such as rising costs post-Brexit.

Bloc plans to bulk-buy key drugs for all 27 countries, potentially leaving Britain ‘behind in the queue’. / “Europe is securing access to key drugs and vaccines as a single region, with huge influence and buying power. As a result of Brexit the UK is now isolated from this system, so our drug supplies could be at risk in the future,” said Dr Andrew Hill, an expert on the pharmaceutical trade.

Medicine shortages in the NHS are 'as bad as they've ever been' as a new report blames Brexit for the supply issues. / Antibiotics, hormone replacement therapy drugs, and ADHD medication are all in short supply this winter with NHS chiefs forced to pay gouged prices in order to fulfil demand.

Patients put at risk as crisis hits supplies of vital antibiotics, HRT and anti-depressants. / Vital antibiotics, hormone replacement therapy (HRT) and attention deficit hyperactivity disorder (ADHD) drugs are among those in desperately short supply this winter – with the NHS forced to pay over the odds to get drugs into Britain.

As of December 2022, UK companies importing medicines from the EU may need to set up new batch testing facilities. What will this mean for the industry and how did the situation come about?

Informa Pharma Intelligence (IPI) has found that some drug firms may withdraw up to 90% of their products from Northern Ireland, once the Brexit grace period has passed.

our out of five drugs used by the NHS will not be allowed into Northern Ireland by January 2022 due to the Protocol, the British Generic Manufacturers Association (BGMA) has warned.

Just seven months after singing its praises, British Prime Minister Boris Johnson is attempting to rewrite the Brexit deal he signed with the European Union.

Firms already starting to withdraw vital drugs because of costly new red tape, says industry group.